Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on VolitionRX. The associated price target remains the same with $2.50.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yi Chen has given his Buy rating due to a combination of factors including VolitionRX’s recent strategic partnership and the potential for future growth. The company has entered into a significant agreement with Werfen, a leader in in vitro diagnostics, to out-license its Nu.Q NETs assay. This partnership is expected to leverage Werfen’s expertise and infrastructure, potentially leading to increased revenue through upfront and milestone payments, as well as future royalties.
Additionally, VolitionRX’s business model, which focuses on licensing revenue and consumable sales, is poised to benefit from expanding interest in its Nu.Q platform for cancer diagnostics. The company’s valuation, supported by a discounted cash flow analysis, suggests a price target of $2.50 per share. However, there are risks such as potential failures in clinical development and securing license agreements, which investors should consider.